Project Grant F31CA301935
- This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $157,980.00 in funding to Dr. Jonathan Rennhack at the Loyola University of Chicago Health Sciences Campus to support research on the role of microenvironmental chemokines in beta-catenin/TCF signaling and gene occupancy during colorectal cancer metastasis to the liver and lung. The key objectives of this research project are to leverage molecular techniques, patient-derived organoids,...
- The National Cancer Institute (NCI) awarded a $1,396,152 Project Grant under the Cancer Biology Research program (CFDA 93.396) to the University of Chicago. The grant, with a project period from December 5, 2024 to November 30, 2029, aims to examine the role of the BNIP3 gene and mitophagy (the selective degradation of mitochondria) in muscle atrophy during cancer cachexia, which is prevalent in pancreatic ductal adenocarcinoma (PDAC). The research will utilize genetically engineered mouse...
- This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $700,690.00 to Health Research, Inc. in Buffalo, NY to support research aimed at deciphering the molecular mechanisms of breast cancer bone metastasis. The 5-year project (04/01/2025 - 03/31/2030) seeks to unravel the biological transition from early-stage microscopic bone metastases to established macro-bone metastases, with a focus on understanding the role of the YAP/TAZ...
- This Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) provides $109,080 to The Trustees of Columbia University in the City of New York to conduct a Phase II, randomized controlled trial evaluating a novel immunotherapeutic approach for treatment-naive metastatic pancreatic adenocarcinoma. The trial will compare a combination regimen of Motixafortide, Cemiplimab, Gemcitabine, and Nab-Paclitaxel against the standard Gemcitabine and Nab-Paclitaxel...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $487,468 to the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University to conduct research on the role of protein palmitoylation in the progression of melanoma lung metastasis. The key objectives of the research project are to: Investigate how the palmitoyl transferase ZDHHC13 suppresses melanoma metastasis by stabilizing E-cadherin through palmitoylation...
- This federal Project Grant award for $778,873, provided by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), supports research conducted by Cold Spring Harbor Laboratory (CSHL) to investigate the role of the enzyme SOAT1 as a potential therapeutic target for pancreatic ductal adenocarcinoma (PDAC). The key objectives of this multi-year (Jun 2025 - May 2030) research project are to use mouse and patient-derived PDAC organoid models to: 1) evaluate the...
- This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $164,500 to The Trustees of Columbia University in the City of New York to investigate the mechanisms by which the protein S100A9 mediates brain metastasis in epidermal growth factor receptor (EGFR)-mutant lung cancer. The key goals are to: Examine how S100A9 expression is epigenetically regulated by histone methylation and the MEIS1 transcription factor in brain metastasis-prone cells....
- This $410,115 Project Grant was awarded by the National Cancer Institute, under the Cancer Biology Research program (CFDA 93.396), to the University of California, San Diego (UC San Diego) to support research aimed at improving preclinical models of metastatic pancreatic cancer. The research project seeks to understand how the collagen-rich tumor microenvironment in pancreatic ductal adenocarcinoma (PDAC) drives metastasis and treatment resistance, and to develop a synthetic 3D high density...
- This $1,480,500 federal Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) aims to elucidate the cell intrinsic and extrinsic mechanisms underlying small cell lung cancer (SCLC) metastasis. The project will develop cutting-edge technologies to establish a comprehensive, spatiotemporally-resolved lineage tracing platform capable of recording the entire course of SCLC metastasis. Specifically, the...
- The National Cancer Institute (NCI) awarded a $730,400 Project Grant under the Cancer Biology Research program (CFDA 93.396) to the Sloan-Kettering Institute for Cancer Research in New York. The goal of this 5-year project is to determine how specific metabolic configurations in lung adenocarcinoma (LUAD) cancer cells support the emergence and maintenance of treatment-resistant cell states. The research team will manipulate components of the tricarboxylic acid (TCA) cycle in mouse and...
ELUCIDATING THE FUNCTIONAL ROLE OF CAMK2B LOSS IN PANCREATIC CANCER METASTASIS - PROJECT SUMMARY PANCREATIC CANCER IS HIGHLY METASTATIC, AND PATIENTS ARE OFTEN NOT DIAGNOSED UNTIL METASTASES HAVE ALREADY FORMED, WITH THE VAST MAJORITY (>75%) PRESENTING WITH OLIGOMETASTATIC DISEASE. CURRENT GENETICALLY ENGINEERED MOUSE MODELS OF PANCREATIC CANCER ARE METASTATIC IN 30-40% OF ANIMALS AND HARBOR ONLY SMALL FOCAL METASTASES, COMPLICATING THE STUDY OF METASTATIC DRIVERS IN MICE. PRELIMINARY EXPERIMENTS IDENTIFIED CALCIUM/CALMODULIN- DEPENDENT PROTEIN KINASE II BETA, CAMK2B, AS A GENE WHOSE LOSS ENHANCES TUMOR METASTASIS AND CREATES A HIGHLY IMMUNOSUPPRESSIVE TUMOR MICROENVIRONMENT (TME). GENETICALLY ENGINEERED MICE WITH TUMOR CELL-SPECIFIC CAMK2B KNOCKOUT FORM METASTASES IN 80% OF ANIMALS AND PRESENT WITH >25 METASTATIC LESIONS PER MOUSE. METASTATIC BURDEN IS SO PROFOUND IN THIS MODEL THAT THE ANIMALS SUCCUMB TO DISEASE TWICE AS FAST AS CONTROL TUMOR BEARING MICE. PRELIMINARY RESULTS, SHOW THAT DELETION OF CAMK2B RESULTS IN TUMORS THAT ARE MORE METASTATIC AND EXPRESS HIGHER LEVELS OF LYSYL OXIDASE (LOX). AIM 1 WILL FOCUS ON EXPLORING TUMOR CELL INTRINSIC MECHANISMS THROUGH WHICH CAMK2B-DELETION PROMOTES TUMOR CELL METASTASIS. THE METASTATIC CASCADE TYPICALLY BEGINS BY THE MODULATION OF TUMOR CELL EPITHELIAL IDENTITY THROUGH PROGRAMS SUCH AS EPITHELIAL-TO-MESENCHYMAL (EMT). THUS, SUBAIM 1.1 WILL INVESTIGATE THE EFFECT OF CAMK2B LOSS ON TUMOR CELL EPITHELIAL CELL IDENTITY USING ISOGENIC CELL LINES, GENETICALLY ENGINEERED MOUSE MODEL, AND PATIENT-DERIVED ORGANOID SYSTEMS. SUBAIM 1.2 WILL INVESTIGATE THE FUNCTIONAL CONTRIBUTION OF LOX ON METASTATIC COMPETENCY AND THE ABILITY OF LOX-TARGETING TO BLOCK METASTATIC OUTGROWTH. PRELIMINARY EXPERIMENTS INDICATE THAT DELETION OF CAMK2B IN TUMOR CELLS SHIFTS THE IMMUNE MILIEU TOWARDS A PRO- TUMOR STATE THAT IS MORE PERMISSIVE TO TUMOR METASTASIS. IN THIS REGARD, CAMK2B-NULL TUMOR CELLS ALTER THEIR LOCAL MICROENVIRONMENT AND CONFER AN IMMUNE DESERT PHENOTYPE THAT MAY FACILITATE TUMOR GROWTH AND METASTASIS. TO EXPLORE MECHANISMS OF THIS IMMUNOSUPPRESSIVE PHENOTYPE, AIM 2 WILL TEST THE CONTRIBUTION OF THE IMMUNOSUPPRESSIVE MICROENVIRONMENT IN CAMK2B-NULL TUMORS ON METASTASIS. SUBAIM 2.1 WILL SELECTIVELY DEPLETE MACROPHAGES IN CAMK2B-DELETION TUMORS AND EVALUATE THE IMPACT ON THE METASTATIC NICHE AND GROSS TUMOR CELL METASTASIS. SUBAIM 2.2 WILL INVESTIGATE THE CONTRIBUTION OF TBC1D9, A CALCIUM-RESPONSIVE GENE ACTIVATED IN CAMK2B DELETED TUMOR CELLS, TO SUPPRESSION OF THE NK AND T CELL RESPONSE. COLLECTIVELY, OUR WORK WILL DEMONSTRATE THAT CAMK2B IS A METASTASIS SUPPRESSING GENE WHOSE LOSS ACTIVATES PRO- METASTATIC SIGNALING NETWORKS. OUR FUNCTIONAL AND MECHANISTIC WORK WILL DEFINE TARGETABLE DOWNSTREAM SIGNALING NODES, WITHIN TUMOR CELLS AND IN THE MICROENVIRONMENT, TO BLOCK IMMUNOSUPPRESSION AND METASTATIC OUTGROWTH.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $37.0k | 7/2/25 | ||
| Not listed | $0 | 7/2/25 | ||
| Not listed | $37.0k | 7/2/25 |